{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:42:59Z","timestamp":1787020979295,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100003135","name":"Minnesota Ovarian Cancer Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003135","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 GM065841"],"award-info":[{"award-number":["T32 GM065841"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA136393"],"award-info":[{"award-number":["P50 CA136393"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA136393"],"award-info":[{"award-number":["P50 CA136393"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA136393"],"award-info":[{"award-number":["P50 CA136393"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA136393"],"award-info":[{"award-number":["P50 CA136393"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA136393"],"award-info":[{"award-number":["P50 CA136393"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA136393"],"award-info":[{"award-number":["P50 CA136393"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007048","name":"Mayo Foundation for Medical Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Cancer Society"},{"name":"Mayo-Karolinska Institutet Collaborative Grant"},{"DOI":"10.13039\/100017909","name":"Fred C. and Katherine B. Andersen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017909","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The prognosis for women with ovarian cancer (OC) is particularly poor if resistance to platinum compounds, the mainstay of standard-of-care therapy, develops. Inhibitors of the Nudix hydrolase MuT Homolog 1 (MTH1) have previously been shown to arrest cancer cells in mitosis, increase 8-oxo-2\u2019-deoxyguanosine (8-oxo-dG) incorporation into DNA, and selectively kill neoplastic cells while sparing normal cells. Here we explored the cytotoxic mechanism of these agents as well as their activity against platinum-resistant OC in vitro and in vivo. Two mitotic MTH1 inhibitors (mMTH1is), TH588 and karonudib, decreased colony formation indistinguishably in platinum-sensitive OC cell lines and their platinum-resistant counterparts in vitro but had limited effects on fallopian tube and immortalized ovarian surface epithelial cells. Treatment with karonudib stalled OC cells in mitosis and caused elevated 8-oxo-dG levels in DNA followed by activation of base excision repair, induction of BAX, and apoptotic cellular demise. This cytotoxicity was blunted by overexpression of the pre-mitotic checkpoint protein CHFR, which inhibits other anti-mitotics, or treatment with the antioxidant N-acetylcysteine, which diminishes nuclear 8-oxo-dG staining, suggesting a role for both mitotic stalling and increased nuclear incorporation of oxidized nucleotides in karonudib efficacy. In three orthotopic OC patient-derived xenograft models, karonudib monotherapy induced growth delay in vivo. Moreover, addition of karonudib to carboplatin doubled median overall survival in two models and prolonged survival for the duration of the study (110 days) in the third. These results demonstrate activity of mMTH1is as monotherapy and in combination with carboplatin in OC that warrants further investigation.<\/jats:p>","DOI":"10.1186\/s40164-025-00681-0","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T05:06:09Z","timestamp":1750655169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity"],"prefix":"10.1186","volume":"14","author":[{"given":"Rachel M.","family":"Hurley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Kanakkanthara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annapoorna","family":"Venkatachalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Deisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine P.","family":"Macon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan P.","family":"Heinzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Sanjiv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa C.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann L.","family":"Oberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. John","family":"Weroha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika Warpman","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Helleday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E. Wahner","family":"Hendrickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"681_CR1","doi-asserted-by":"publisher","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","volume":"2","author":"UA Matulonis","year":"2016","unstructured":"Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061.","journal-title":"Nat Rev Dis Primers"},{"issue":"10177","key":"681_CR2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240\u201353.","journal-title":"Lancet"},{"key":"681_CR3","doi-asserted-by":"crossref","unstructured":"McMullen M, Karakasis K, Madariaga A, Oza AM. Overcoming platinum and PARP-Inhibitor resistance in ovarian cancer. Cancers (Basel). 2020;12(6).","DOI":"10.3390\/cancers12061607"},{"key":"681_CR4","doi-asserted-by":"crossref","unstructured":"Elyashiv O, Aleohin N, Migdan Z, Leytes S, Peled O, Tal O et al. The poor prognosis of acquired secondary platinum resistance in ovarian cancer patients. Cancers (Basel). 2024;16(3).","DOI":"10.3390\/cancers16030641"},{"key":"681_CR5","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1038\/ncomms4128","volume":"5","author":"R Nilsson","year":"2014","unstructured":"Nilsson R, Jain M, Madhusudhan N, Sheppard NG, Strittmatter L, Kampf C, et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun. 2014;5:3128.","journal-title":"Nat Commun"},{"issue":"7","key":"681_CR6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/annonc\/mdu158","volume":"25","author":"T Helleday","year":"2014","unstructured":"Helleday T. Cancer phenotypic lethality, exemplified by the non-essential MTH1 enzyme being required for cancer survival. Ann Oncol. 2014;25(7):1253\u20135.","journal-title":"Ann Oncol"},{"issue":"7495","key":"681_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature13181","volume":"508","author":"H Gad","year":"2014","unstructured":"Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Strom CE, et al. MTH1 Inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 2014;508(7495):215\u201321.","journal-title":"Nature"},{"key":"681_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-3-031-30065-3_13","volume":"186","author":"T Helleday","year":"2023","unstructured":"Helleday T. Mitotic MTH1 inhibitors in treatment of cancer. Cancer Treat Res. 2023;186:223\u201337.","journal-title":"Cancer Treat Res"},{"issue":"17","key":"681_CR9","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1158\/0008-5472.CAN-19-0883","volume":"80","author":"SG Rudd","year":"2020","unstructured":"Rudd SG, Gad H, Sanjiv K, Amaral N, Hagenkort A, Groth P, et al. MTH1 inhibitor TH588 disturbs mitotic progression and induces mitosis-dependent accumulation of genomic 8-oxodG. Cancer Res. 2020;80(17):3530\u201341.","journal-title":"Cancer Res"},{"issue":"6794","key":"681_CR10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/35019108","volume":"406","author":"DM Scolnick","year":"2000","unstructured":"Scolnick DM, Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature. 2000;406(6794):430\u20135.","journal-title":"Nature"},{"key":"681_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/cancers13236043","volume":"13","author":"AE Wahner Hendrickson","year":"2021","unstructured":"Wahner Hendrickson AE, Visscher DW, Hou X, Goergen KM, Atkinson HJ, Beito TG, et al. CHFR and paclitaxel sensitivity of ovarian cancer. Cancers (Basel). 2021;13:23.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"681_CR12","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3109\/10715762.2011.591391","volume":"45","author":"T Itoh","year":"2011","unstructured":"Itoh T, Terazawa R, Kojima K, Nakane K, Deguchi T, Ando M, et al. Cisplatin induces production of reactive oxygen species via NADPH oxidase activation in human prostate cancer cells. Free Radic Res. 2011;45(9):1033\u20139.","journal-title":"Free Radic Res"},{"issue":"11","key":"681_CR13","doi-asserted-by":"publisher","first-page":"e81162","DOI":"10.1371\/journal.pone.0081162","volume":"8","author":"R Marullo","year":"2013","unstructured":"Marullo R, Werner E, Degtyareva N, Moore B, Altavilla G, Ramalingam SS, et al. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS ONE. 2013;8(11):e81162.","journal-title":"PLoS ONE"},{"issue":"11","key":"681_CR14","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.cell.2023.04.026","volume":"186","author":"J Zhang","year":"2023","unstructured":"Zhang J, Simpson CM, Berner J, Chong HB, Fang J, Ordulu Z, et al. Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway. Cell. 2023;186(11):2361\u2013e7925.","journal-title":"Cell"},{"issue":"8Supplement","key":"681_CR15","doi-asserted-by":"publisher","first-page":"CT182","DOI":"10.1158\/1538-7445.AM2023-CT182","volume":"83","author":"J Yachnin","year":"2023","unstructured":"Yachnin J, Ny L, Sandvall T, Sanjiv K, Scobie M, Platzack B, et al. Abstract CT182: OXC-101 shows favorable safety profile in first in human phase 1 trial in patients with advanced solid cancer. Cancer Res. 2023;83(8Supplement):CT182\u2013CT.","journal-title":"Cancer Res"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00681-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00681-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00681-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T05:06:12Z","timestamp":1750655172000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00681-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["681"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00681-0","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"5 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PDXs were generated under protocols approved by the Mayo Clinic Institutional Review Board (approval # 09-008768) and Mayo Clinic Animal Care and Use Committee (approval # A37615). Treatments with carboplatin and karonudib were conducted under the aegis of Mayo Clinic Animal Care and Use Committee protocol A00005570-20.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"U.W.B., T.H. and K.S. are shareholders in Oxcia AB. In addition, U.W.B. is CEO and board member of Oxcia AB; T.H. is board member of Oxcia AB; and A.W.H. serves on the advisory board of Oxcia AB. The other authors report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}